Article Information
History
- April 8, 2021.
Article Versions
- Version 1 (November 12, 2020 - 14:19).
- Version 2 (November 13, 2020 - 05:24).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Daniel D. Murray1,
- Abdel G. Babiker2,
- Jason V. Baker3,4,
- Christina E. Barkauskas5,
- Samuel M. Brown6,7,
- Christina C. Chang8,
- Victoria J. Davey9,
- Annetine C. Gelijns10,
- Adit A. Ginde11,
- Birgit Grund12,
- Elizabeth Higgs13,
- Fleur Hudson14,
- Virginia L. Kan15,16,
- H. Clifford Lane13,
- Thomas A. Murray12,
- Roger Paredes17,
- Mahesh K.B. Parmar14,
- Sarah Pett2,18,
- Andrew N. Phillips18,
- Mark N. Polizzotto8,19,
- Cavan Reilly12,
- Uriel Sandkovsky20,
- Shweta Sharma12,
- Marc Teitelbaum21,
- B. Taylor Thompson22,23,
- Barnaby E. Young24,25,26,
- James D. Neaton12,
- Jens D. Lundgren1 and
- on behalf of the TICO Study Group
- 1CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
- 2Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK
- 3Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
- 4University of Minnesota, Minneapolis, MN, USA
- 5Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University, Durham, NC 27710, USA
- 6Intermountain Medical Center, Murray, UT, USA
- 7University of Utah School of Medicine, Salt Lake City, UT, USA
- 8The Kirby Institute, University of New South Wales, Sydney, Australia
- 9U.S. Department of Veterans Affairs, Washington, D.C., USA
- 10Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 11Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
- 12Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA
- 13National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
- 14MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London
- 15Veteran Affairs Medical Center, Washington, D.C., USA
- 16George Washington University School of Medicine and Health Sciences, Washington, D.C., USA
- 17Infectious Diseases Department & irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Catalonia, Spain
- 18Institute for Global Health, University College London, London, UK
- 19St Vincent’s Hospital, Sydney, Australia
- 20Division of Infectious Diseases, Baylor University Medical Center, Dallas, TX, USA
- 21Leidos Biomedical Research, Inc., Frederick, MD, USA
- 22Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- 23Harvard Medical School Boston, MA, USA
- 24National Centre for Infectious Diseases, Singapore, Singapore
- 25Tan Tock Seng Hospital, Singapore, Singapore
- 26Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
- * Corresponding author; email: daniel.dawson.murray{at}regionh.dk
Posted April 08, 2021.
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)
